FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 331:275-276 July 28, 1994 Number 4 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Carpenter, W. T.

To the Editor: Carpenter and Buchanan provide a succinct yet comprehensive overview of schizophrenia (March 10 issue)¹. Their article presents a fairly clear discussion of the diagnosis, course, and outcome; epidemiology and causes; and pathophysiology of this troubling illness. But their thoroughly referenced review does not mention the newly approved drug risperidone and fails to note any potential benefits associated with a strong treatment alliance.

Risperidone has been shown to be an effective antipsychotic agent, improving both the positive and negative symptoms of schizophrenia yet having less potential for producing extrapyramidal symptoms at therapeutic doses^2,3,4,5. This benzisoxazole derivative . . . [Full Text of this Article]

References

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.